The first medical condition that Philae will target is Epidermolysis Bullosa (EB), a very rare but lethal disorder for which there is presently no treatment or cure. Patients with EB are known as ‘butterfly children’ because their skin is as fragile as a butterfly’s wings. The slightest amount of contact or friction can cause serious damage to their skin.
Philae Pharmaceuticals was founded by the late Professor Marcel Jonkman, previously Head of Dermatology at UMCG, Dick Kellogg, Emeritus Professor of Organic Chemistry, and Dr Reinier Schwietert, Pharmacologist.
Investment fund Pharma Connect Capital (PCC) invests in very early-stage medicine development, drug delivery and biomarkers from the High Throughput Screening phase up to Phase 1 (sometimes Phase 2) and other projects...
These cookies make sure the website functions properly. These cookies also provide us to anonymously monitor website statistics. Because these cookies are essential for the website, you can not disable them without compromising the functionality of the website.
These cookies collect data that we use to understand how our website is used and perceived. These cookies also help us to optimize the website for the best user experience.
These cookies allow ad-networks to monitor your online behaviour so they can display relevant ads based on your interest and online behaviour. These cookies also prevent the same ads from being displayed over and over.